Treatment of ankylosing spondylitis during pregnancy

Aims of the trial – to study the frequency of drug use in pregnant women with ankylosing spondylitis (AS), to determine the effect of discontinuation of drugs of various groups, as well as the dose of non-steroidal anti-inflammatory drugs (NSAIDs) used, on AS activity during gestation.

Material and methods. 50 pregnancies in 49 patients with AS that met the modified New York criteria of 1984. The average age of the patients was 31.7±4.9 years, the duration of the disease was 134.4±85.8 months. The visits were conducted at 10–11, 20–21 and 31–32 weeks of gestation. The BASDAI in the month of conception and in the I, II and III trimesters of pregnancy was: 1.4 [0.6; 3.3], 2.3 [1.2; 4.4], 2.8 [1.4; 4.2] and 2.2 [1.6; 4.0], respectively. The total dose of NSAIDs was determined by the NSAID intake index (Dougados M., 2011).

Results and discussion. NSAIDs. After inclusion in the study, the drug of choice was ibuprofen, which was canceled for all women not later than on 32 week of gestation. At the time of conception and in the first, second and third trim. NSAIDs were taken by 23 (46%), 20 (40%), 30 (60%) and 21 (43.8%) women, respectively. NSAIDs intake index in I trimester (5.8 [2.9; 11.8]) was lower than before pregnancy (28.6 [16.7; 50]) and in II (15.5 [4.7; 30.9]) and III trimesters (24.4 [9.5; 50]) (p<0.05). No relationship between the index of ibuprofen intake, as well as the fact of withdrawal of NSAIDs and AS activity throughout gestation was found.
Sulfasalazine (SS) in correspondence with arthritis was taken 3 months before conception by 11 (22%) women, during pregnancy – by 6 (12%) women at a dose of 1.25±0.25 g. Withdrawal of SS was not associated with recurrence of arthritis.
Glucocorticoids (GC) at a dose of 7.5±2.5 mg 3 months before pregnancy and in the I, II and III trimesters of pregnancy were taken by 1 (2%), 4 (8%), 8 (16%) and 10 (20.8%) women, of whom 1 patient had arthritis and 1 had inflammatory bowel disease. The rest of the patients received GC due to high AS activity due to axial manifestations and the unavailability of TNFα inhibitors. Against the background of taking GC, the AS activity did not decrease: BASDAI in the II and III trimesters was 5.5±0.6 and 5.8±1.3 (p>0.05).
TNFα inhibitors: 3 months before pregnancy and in the trim. of pregnancy were taken by 11 (22%), 7 (14%), 6 (12%) and 2 (4.2%) patients. In those who canceled therapy (both independently and on the recommendation of a rheumatologist) on the eve of pregnancy, an increase in AS activity was noted; BASDAI in the month of conception and in I, II, III trimesters was: 2.7 [0.8; 3.5], 5.1 [3.1; 5.9], 5.5 [5; 6] and 6.7 [5.3; 7.3] (p<0.05) compared to the month of conception. Cancellation of TNF-α in the month of conception was a risk factor for high AS activity (BASDAI>4) in the II trimester (OR=30.4; 95% CI: 1.5–612.3; p=0.03) and in the III trimester (OR=32.7; 95% CI: 1.6–662.2; p=0.02).

Conclusion. NSAIDs and GC in low doses do not reduce the activity of AS. Withdrawal of TNF-α inhibitors on the eve of pregnancy is a predictor of high AS activity. It is necessary to increase the knowledge of rheumatologists and patients about the therapeutic possibilities during pregnancy to avoid unjustified drug withdrawal.

1. Ushkalova EA, Tkacheva ON, Chukhareva NA. The problem of the safety of the use of medicines during pregnancy and lactation. Obstetrics and Gynecology. 2011;(2):4-7 (In Russ.).

2. Gandaloeva ZM, Krichevskaya OA, Glukhova SI, Dubinina TV, Lila AM, et al. Pregnancy with ankylosing spondylitis: the view of the patient and the doctor. Modern Rheumatology Journal. 2019;13(1):71-79 (In Russ.). doi: 10.14412/1996-7012-2019-1-71-79

3. Gotestam Skorpen C, Hoeltzenbein M, Tincani A, FischerBetz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795810. doi: 10.1136/annrheumdis-2015-208840

4. Kosheleva NM. Pregnancy planning and monitoring of pregnant women with rheumatic diseases. In: Nasonov EL (ed.). Rheumatology. Russian clinical recommendations. Moscow:GEOTAR-Media;2017:380-389 (In Russ.).

5. Tincani A, Taylor P, Fischer-Betz R, Ecoffet C, Chakravarty E. Fears and misconceptions of women with chronic rheumatic diseases on their journey to motherhood. Ann Rheum Dis. 2018;77(Suppl):A866. doi: 10.1136/annrheumdis-2018-eular.2063

6. Haroun T, Eudy AM, Jayasundara M, Nowell WB, Curtis JR, White CW, et al. Tough choices: Understanding the medication decision-making process for women with inflammatory arthritis during pregnancy and lactation. ACR/ARHP Annual Meeting. San Diego, CA;2017 Nov 3-8, 2017:Abstract 1298.

7. Smolen JS, Gladman D, McNeil HP, Mease PJ, Sieper J, Hojnik M, et al. Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: A large crosssectional study. RMD Open 2019;5:e000585. doi: 10.1136/rmdopen-2017-000585

8. Michetti P, Weinman J, Mrowietz U, Smolen J, Peyrin-Biroulet L, Louis E, et al. Impact of treatment-related beliefs on medication adherence in immune-mediated inflammatory diseases: Results of the global ALIGN study. Adv Ther. 2017;34(1):91-108. doi: 10.1007/s12325-016-0441-3

9. van den Brandt S, Zbinden A, Baeten D, Villiger PM, Østensen M, Förger F. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients. Arthritis Res Ther. 2017;19(1):64. doi: 10.1186/s13075-017-1269-1

10. Genest G, Spitzer KA, Laskin CA. Maternal and fetal outcomes in a cohort of patients exposed to tumor necrosis factor inhibitors throughout pregnancy. J Rheumatol. 2018;45(8):1109-1115. doi: 10.3899/jrheum.171152

11. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, BurgosVargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: A guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(2):ii1-ii44. doi: 10.1136/ard.2008.104018

12. Dougados M. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis. 2011;70:249-251. doi: 10.1136/ard.2010.133488

13. Shalansky SJ, Levy AR, Ignaszewski AP. Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Ann Pharmacother. 2004;38:1363-1368.

14. Ostensen M, Husby G. A prospective clinical study of the effect of pregnancy on rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum. 1983;26(9):1155-1159.

15. Timur H, Tokmak A, Turkmen GG, Ali İnal H, Uygur D, Danışman N. Pregnancy outcome in patients with ankylosing spondylitis. J Matern Fetal Neonatal Med. 2016;29(15):2470-2474. doi: 10.3109/14767058.2015.1089432

16. Ursin K, Lydersen S, Skomsvoll JF, Wallenius M. Disease activity during and after pregnancy in women with axial spondyloarthritis: A prospective multicentre study. Rheumatology (Oxford). 2018;57(6):1064-1071. doi: 10.1093/rheumatology/key047

17. Zbinden A, van den Brandt S, Ostensen M, Villiger PM, Förger F. Risk for adverse pregnancy outcome in axial spondyloarthritis and rheumatoid arthritis: Disease activity matters. Rheumatology. 2018;57:1235-1242. doi: 10.1093/rheumatology/key053

18. Smith CJF, Bandoli G, Kavanaugh A, Chambers CD. Birth outcomes and disease activity during pregnancy in a prospective cohort of women with psoriaric arthritis and ankylosing spondylitis. Arthritis Care Res (Hoboken). 2020;72(7):1029-1037. doi: 10.1002/acr.23924

19. Krichevskaya OA, Gandaloeva ZM, Dubinina TV. Ankylosing spondylitis and pregnancy: A modern view of the problem. Modern Rheumatology Journal. 2018;12(3):19-28 (In Russ.). doi: 10.14412/1996-7012-2018-3-19-28